Treatment strategies in controlling strongyloidiasis

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 11, 2004, Pages 2293-2301

  Satoh, Masao ^a   Kokaze, Akatsuki ^b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b KYORIN UNIVERSITY   (Japan)

Author keywords

Autoinfection; Complication; Ivermectin; Opportunistic infection; Strongyloidiasis

Indexed keywords

ALBENDAZOLE; IVERMECTIN; MEBENDAZOLE; TIABENDAZOLE;

ABDOMINAL PAIN; ANOREXIA; ANTIBODY DETECTION; BACTERIAL MENINGITIS; BLOOD SAMPLING; BRAIN ABSCESS; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ECHINOCOCCOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FECES ANALYSIS; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T CELL LEUKEMIA VIRUS 1; INFECTION RISK; LIVER DYSFUNCTION; NAUSEA; ONCHOCERCIASIS; PSYCHOPATHY; REVIEW; RISK FACTOR; STRONGYLOIDES STERCORALIS; STRONGYLOIDIASIS; TRAVEL; TREATMENT OUTCOME;

ANTINEMATODAL AGENTS; BENZIMIDAZOLES; HUMANS; IVERMECTIN; STRONGYLOIDIASIS;

EID: 8544238527     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.11.2293     Document Type: Review

References (97)

1. GROVE DI: Human strongyloidiasis. Adv. Parasitol. (1996) 38:251-309.
2. KEISER PB, NUTMAN TB: Strongyloides stercoralis in the immunocompromised population. Clin. Microbiol. Rev. (2004) 17 208-217.
3. GILL GV, BEECHING NJ, KHOO S et al.: A british second world war veteran with disseminated strongyloidiasis. Trans. R. Soc. Trop. Med. Hyg. (2004) 98:382-386.
4. GENTA RM, WEESNER R, DOUCE RW, HUITGER-O'CONNOR T, WALZER PD: Strongyloidias is in US veterans of the Vietnam and other wars. JAMA (1987) 258:49-52.
5. SIDDIQUI AA, BERK SL: Diagnosis of Strongyloides stercoralis infection. Clin. Infect. Dis. (2001) 33:1040-1047.
6. HEYWORTH MF: Parasitic diseases in immunocompromised hosts. Cryptosporidiosis, isosporiasis, and strongyloidiasis. Gastroenterol. Clin. North Am. (1996) 25:691-707.
7. SATOH M, FUTAMI A, TAKAHIRA K et al.: Severe strongyloidiasis complicated by meningitis and hydrocephalus in an HTLV-1 carrier with increased proviral load. J. Infect. Chemother. (2003) 9:355-357.
8. VISHWANATH S, BAKER RA, MANSHEIM BJ: Strongyloides infection and meningitis in an immunocompromised host. Am. J. Trop. Med. Hyg. (1982) 31:857-858.
9. MAAYAN S, WORMSER GP, WIDERHORN J, ERNSTO RS, KIM YH, ERNST JA: Strongyloides stercoralis hyperinfection in a patient with the acquired immune deficiency syndrome. Am. J. Med. (1987) 83 945-948.
10. IGA-SIEGMAN Y, KAPILA R, SEN P, KAMINSKI ZC, LOURIA DB: Syndrome of hyperinfection with Strongyloides stercoralis. Rev. Infect. Dis. (1981) 3:397-407.
11. LESSNAU KD, CAN S, TALAVERA W: Disseminated strongyloides stercoralis in human immunodeficiency virus-infected patients. Chest (1993) 104:119-122.
12. ADEDAYO AO, GRELL GAC, BELLOT P: Case study: Fatal strongyloidiasis associated with human T-cell lymphotropic virus Type 1 infection. Am. J. Trop. Med. Hyg. (2001) 65:650-651.
13. GOTUZZO E, TERASHIMA A, ALVAREZ H et al.: Strongyloides stercoralis hyperinfection associated with human T-cell lymphotropic virus Type 1 infection in Peru. Am. J. Trop. Med. Hyg. (1999) 60:146-149.
14. CAHILL KM, SHEVCHUK M: Fulminant, systemic strongyloidiasis in AIDS. Ann. Trop. Med. Parasitol. (1996) 90:313-318.
15. COOVADIA YM, RAJPUT MC, BHANA RH: Disseminated strongyloidiasis in a diabetic patient. Trop. Geogr. Med. (1993) 45:179-180.
16. ASHRAF M, GUE CL, BADDOUR LM: Case report: strongyloidiasis refractory to treatment with ivermectin. Am. J. Med. Sci. (1996) 311:178-179.
17. SATOH M, TOMA H, SATO Y et al.: Reduced efficacy of treatment of strongyloidiasis in HTLV-1 carriers related to enhanced expression of IFN-γ and TGF-β1. Clin. Exp. Immunol. (2002) 127 354-3 59.
18. ALBONICO M, CROMPTON DWT, SAVIOLI L: Control strategies for human intestinal nematode infections. Adv. Parasitol. (1999) 42 277-341.
19. ZAHA O, HIRATA T, KINJO F, SAITO A: Strongyloidiasis-progress in diagnosis and treatment. Intern. Med. (2000) 39:695-700.
20. SHIKIYA K, KINJO N, IKEMA M et al.: Comparison of efficacy on powder and tablet of mebendazole in the treatment of strongyloidiasis. Kansenshogaku Zasshi (1991) 65:681-686
21. GROVE DI: Strongyloides ratti and S. stercoralis: the effects of thiabendazole, mebendazole, and cambendazole in infected mice. Am. J. Trop. Med. Hyg. (1982) 31: 469-476.
22. SHIKIYA K, ZAHA O, NIIMURA S et al.: Long term eradication rate of mebendazole therapy for strongyloidiasis. Kansenshogaku Zasshi (1992) 66:354-359
23. MCMANUS DP, ZHANG W, LI J, BARTLEY PB: Echinococcosis. Lancet (2003) 362:1295-1304.
24. HORTON J: Albendazole: a review of anthelmintic efficacy and safety in humans. Parasitology (2000) 121:S113-S132.
25. PENE P, MOJON M, GARIN JP, COULAUD JP, ROSSIGNOL JF: Albendazole: a new broad spectrum anthelmintic double-blind multicenter clinical trial. Am. J. Trop. Med. Hyg. (1982) 31:263-266.
26. ROSSIGNOL JF, MAISONNEUVE H: Albendazole: placebo-controlled study in 870 patients with intestinal helminthiasis. Trans. R. Soc. Trop. Med. Hyg. (1983) 77:707-711.
27. NIIMURA S, HIRATA T, ZAHA O et al.: Clinical study of albendazole therapy for strongyloidiasis. Kansenshogaku Zasshi (1992) 66:1231-1235 (In Japanese, Abstract in English).
28. TOMA H, SATO Y, KOBAYASHI J et al.: Treatment of strongyloidiasis with albendazole in Okinawa, Japan. Jpn. J. Parasitol. (1993) 42:300-307 (In Japanese, Abstract in English).
29. GROVE DI: Treatment of strongyloidiasis with thiabendazole: an analysis of toxicity and effectiveness. Trans. R. Soc. Trop. Med. Hyg. (1982) 76:114-118.
30. OYAKAWA T, KUNIYOSHI T, ARAKAKI T et al.: New trial with thiabendazole for treatment of human strongyloidiasis. Kansenshogaku Zasshi (1991) 65:304-310 (In Japanese, Abstract in English).
31. BOKEN DJ, LEONI PA, PREHEIM LC: Treatment of Strongyloides stercoralis hyperinfection syndrome with thiabendazole administered per rectum. Clin. Infect. Dis. (1993) 16:123-126.
32. BROWN KR, RICCI FM, OTTESEN EA: Ivermectin: effectiveness in lymphatic filariasis. Parasitology (2000) 121:S133-S146.
33. ZAHA O, HIRATA T, KINJO F, SAITO A: Ivermectin in clinical practice. In: Macrolide Antibiotics. Omura S (Ed.), Academic Press, San Diego, USA (2002):403-419.
34. SHIKIYA K, KINJO N, UEHARA T et al.: Efficacy of ivermectin against Strongyloides stercoralis in humans. Intern. Med. (1992) 31:310-312.
35. ADENUSI AA: Cure by ivermectin of a chronic, persistent, intestinal strongyloidosis. Acta Trop. (1997) 66:163-167.
36. ARENA JP, LIU KK, PARESS PS, CULLY DF: Avermectin-sensitive chloride currents induced by Caenorhabditis elegans RNA in Xenopus oocytes. Mol. Pharmacol. (1991) 40:368-374.
37. ARENA JP, LIU KK, PARESS PS, SCHAEFFER JM, CULLY DF: Expression of a glutamate-activated chloride current in Xenopus oocytes injected with Caenorhabditis elegans RNA: evidence for modulation by avermectin. Mol. Brain Res. (1992) 15:339-348.
38. ARENA JP, LIU KK, PARESS PS et al.: The mechanism of action of avermectins in Caenorhabditis elegans: correlation between activation of glutamate-sensitive chloride current, membrane binding, and biological activity. J. Parasitol. (1995) 81:286-294.
39. MARTI H, HAJI HJ, SAVIOLI L et al.: A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children. Am. J. Trop. Med. Hyg. (1996) 55:477-481.
40. FREEDMAN DO, ZIERDT WS, LUJAN A, NUTMAN TB: The efficacy of ivermectin in the chemotherapy of gastrointestinal helminthiasis in humans. J. Infect. Dis. (1989) 159:1151-1153.
41. SHIKIYA K, ZAHA O, NIIMURA S et al.: Clinical study on ivermectin against 125 strongyloidiasis patients. Kansenshogaku Zasshi (1994) 68:13-20 (In Japanese, Abstract in English).
42. YOSHIDA M, MIYOSHI I, HINUMA Y: Isolation and characterization of retro-virus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc. Natl. Acad. Sci. USA (1982) 79:2031-2035.
43. YOSHIDA M, SEIKI M, YAMAGUCHI K, TAKATSUKI K: Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc. Natl. Acad. Sci. USA (1984) 81 2534-2537.
44. GESSAIN A, BARIN F, VERNANT JC et al.: Antibodies to human T lymphotropic virus type-I in patients with tropic spastic paraparesis. Lancet (1985) 2:407-410.
45. OSAME M, USUKU K, IZUMO et al.: HTLV-I-associated myelopathy, a new clinical entity. Lancet (1986) 1:1031-1032.
46. MOCHIZUKI M, YAMAGUCHI K, TAKATSUKI K, WATANABE T, MON S, TAJIMA K: HTLV-I and uveitis. Lancet (1992) 339:1110.
47. MOCHIZUKI M, WATANABE T, YAMAGUCHI K et al.: An uveitis associated with human T-lymphotropic virus type-I (HTLV-I):seroepidemiological, clinical and virological studies. J. Infect. Dis. (1992) 166:943-944.
48. TAJIMA K, CARTIER L: Epidemiological features of HTLV-1 and adult T cell leukemia. Intervirology (1995) 38:238-246.
49. SATOH M, TSUKIDATE S, FUJITA K, YAMAMOTO K: Strongyloidiasis influences the elevation of adult T-cell leukemia-associated antigen antibody titer. Int. Arch. Allergy. Appl. Immunol. (1991) 96 95-96.
50. HINUMA Y, IMAI J: Epstein-Barr virus-specific antibodies in patients with adult T-cell leukemia (ATL) and healthy ATL virus-carriers. Int. J. Cancer. (1983) 31:197-200.
51. PORTO AF, FILHO JO, NEVA FA et al.: Influence of human T cell lymphotropic virus type-1 infection on serologic and skin tests for strongyloidiasis. Am. J. Trop. Med. Hyg. (2001) 65 610-613.
52. NEWTON RC, LIMPUANGTHIP P, GREENBERG S, GAM A, NEVA FA: Strongyloides stercoralis hyperinfection in a carrier of HTLV-I virus with evidence of selective immunosuppression. Am. J. Med. (1992) 92:202-208.
53. HIRATA T, SAITO A: Strongyloidiasis. Nippon Rinsho (2003) 61:S644-S648 (In Japanese).
54. ZAHA O, HIRATA T, KINJO F, SAITO A, FUKUHARA H: Efficacy of ivermectin for chronic strongyloidiasis: two single doses given 2 weeks apart. J. Infect. Chemother. (2002) 8:94-98.
55. TARR PE, MIELE PS, PEREGOY KS, SMITH MA, NEVA FA, LUCEY DR: Case report: rectal administration of ivermectin to a patient with Strongyloides hyperinfection syndrome. Am. J. Trop. Med. Hyg. (2003) 68:453-455.
56. MEINKING TL, TAPLIN D, HERMIDA JL, PARDO R, KERDEL FA: The treatment of scabies with ivermectin. N. Engl. J. Med. (1995) 333:26-30.
57. SANTRO AF, REZAC MA, LEE JB: Current trend in ivermectin usage for scabies. J. Drugs. Dermatol. (2003) 2:397-401.
58. LOUTFY MR, WILSON M, KEYSTONE JS, KAIN KC: Serology and eosinophil count in the diagnosis and management of strongyloidiasis in a non-endemic area. Am. J. Trop. Med. Hyg. (2002) 66:749-752.
59. ROMAN-SANCHEZ P, PASTOR-GUZMAN A, MORENO-GUILLEN S, IGUAL-ADELL R, SUNER-GENEROSO S, TORNERO-ESTEBANEZ C: High prevalence of Strongyloides stercoralis among farm workers on the mediterranean coast of Spain: analysis of the predictive factors of infection in developed countries. Am. J. Trop. Med. Hyg. (2003) 69:336-340.
60. ROBINSON RD, LINDO JF, NEVA FA et al.: Immunoepidermiologic studies of Strongyloides stercoralis and human T lymphotropic virus Type 1 infections in Jamaica. J. Infect. Dis. (1994) 169:692-696
61. SATO Y, KOBAYASHI J, TOMA H, SHIROMA Y: Efficacy of stool examination for detection of Strongyloides infection. Am. J. Trop. Med. Hyg. (1995) 53:248-250.
62. JONES CA, ABADIE SH: Studies in human strongyloidiasis. II. A comparison o the efficiency of diagnosis by examination of feces and duodenal fluid. Am. J. Clin. Pathol. (1954) 24:1154-1158.
63. RITCHIE LS: An ether sedimentation technique for routine stool examinations. Bull. US Army Med. Dep. (1948) 8:326.
64. HARADA T, MORI O: A new method for culturing hookworm. Yonago. Acta Med. (1955) 1:177-179.
65. KAMINSKY RG: Evaluation of three methods for laboratory diagnosis of Strongyloides stercoralis infection. J. Parasitol. (1993) 79:277-280.
66. ARAKAKI T, HASEGAWA H, ASATO R et al.: A new method to detect Strongyloides stercoralis from human stool. Jpn. J. Trop. Med. Hyg. (1988) 16:11-17.
67. HARRIS RA, MUSHER DM, FAINSTEIN V, YOUNG EJ, CLARRDGE J: Disseminated strongyloidiasis. Diagnosis made by sputum examination. J. Am. Med. Assoc. (1980) 244:65-66.
68. PERALTA NR, RODRIGUES MA: Strongyloides stercoralis larva in gastric and duodenal aspirates. Acta. Cytol. (1978) 22:61-62.
69. SNOWDEN EB, SCHAFFNER W, STONE WJ: Overwhelming strongyloidiasis: an unappreciated opportunistic infection. Medicine (Baltimore) (1978) 57:527-544.
70. RIFAAT MA, GHANAM NS, EL-KANESHY MH, EL-KHOLY EL-SI, HEGAZI MM, ALI M EL-M: Letter: a case of genitro-urinary strongyloidiasis. Trans. R. Soc. Trop. Med. Hyg. (1973) 67:722-723.
71. SATO Y, TAKARA M, SHIROMA Y: Detection of antibodies in strongyloidiasis by enzyme-linked immunosorbent assay (ELISA). Trans. R. Soc. Trop. Med. Hyg. (1985) 79:51-55.
72. GAM AA, NEVA FA, KROTOSKI WA: Comparative sensitivity and specificity of ELISA and IHA for serodiagnosis of strongyloidiasis with larval antigens. Am. J. Trop. Med. Hyg. (1987) 37:157-161.
73. SATO Y, TOMA H, KIYUNA S, SHIROMA Y: Gelatin particle indirect agglutination test for mass examination for strongyloidiasis. Trans. R. Soc. Trop. Med. Hyg. (1991) 85:515-518.
74. GROVE DI, BLAIR AJ: Diagnosis of human strongyloidiasis by immunofluorescence, using Strongyloides ratti and S. stercoralis larvae. Am. J. Trop. Med. Hyg. (1981) 30:344-349.
75. SATO Y, TOMA H, TAKARA M, SHIROMA Y: Application of enzyme-linked immunosorbent assay for mass examination of strongyloidiasis in Okinawa, Japan. Int. J. Parasitol. (1990) 20 1025-1029.
76. MEDINA LS, HEIKEN JP, GOLD RP: Pipestem appearance of small bowel in strongyloidiasis is not pathognomonic of fibrosis and irreversibility. Am. J. Roentgenol. (1992) 159:543-544.
77. WOODRING JH, HALFHILL H, REED JC: Pulmonary strongyloidiasis: clinical and imaging features. Am. J. Roentgenol. (1994) 162 537-542.
78. CHEN JJ, LEE CM, CHANGCHAN CS: Duodenal Strongyloides stercoralis infection. Endoscopy (1994) 26:272.
79. GROVE DI: Treatment. In: Strongyloidiasis: a major round worm infection of man. Grove DI (Ed.), Taylor & Francis, Philadelphia, USA (1989):199-231.
80. SHIROMA Y, KIYUNA S, SATO Y: Clinical studies on human strongyloidiasis in Okinawa. Jpn. J. Parasitol. (1990) 39 277-283
81. YU JJ, LU SC, WU IH, YU MC, LEE CN, LIN TP: Disseminated Strongyloides stercoralis infection mimicking pneumonia. J. Formos. Med. Assoc. (1995) 94:S162-S165.
82. CASATI A, CORNERO G, MUTTINI S, TRESOLDI M, GALLIOLI G, TORRI G: Hyperacute pneumonitis in a patient with overwhelming Strongyloides stercoralis infection. Eur. J. Anaesthesiol. (1996) 13 498-501.
83. O'BRIEN W. Intestinal malabsorption in acute infection with Strongyloides stercoralis. Trans. R. Soc. Trop. Med. Hyg. (1975) 69:69-77.
84. MILDER JE, WALZER PD, KILGORE G, RUTHERFORD I, KLEIN M: Clinical features of Strongyloides stercoralis infection in an endemic area of the United States. Gastroenterology (1981) 80 1481-1488.
85. GENTA, RM: Immunology. In: Strongyloidiasis: a major round worm infection of man. Grove DI (Ed.), Taylor & Francis, Philadelphia, USA (1989): 133-153.
86. GENTA RM: Dysregulation of strongyloidiasis: a new hypothesis. Clin. Microbiol. Rev. (1992) 5:345-355.
87. DAUBENTON JD, BUYS HA, HARTLEY PS: Disseminated strongyloidiasis in a child with lymphoblastic lymphoma. J. Pediatr. Hematol. Oncol. (1998) 20:260-263.
88. KAMIO T, IRIE J, SHIGEMATSU K et al.: An autopsy case of diffuse pulmonary hemorrhage due to disseminated strongyloidiasis in the postpartum state. Pathol. Clin. Med. (1993) 11:1441-1445
89. GANN PH, NEVA FA, GAM AA: A randomized trial of single- and two-dose ivermectin versus thiabendazole for treatment of strongyloidiasis. J. Infect. Dis. (1994) 169:1076-1079.
90. DATRY A, HILMARSDOTTIR I, MAYORGA-SAGASTUME R et al.: Treatment of Strongyloides stercoralis infection with ivermectin compared with albendazole: results of an open study of 60 cases. Trans. R. Soc. Trop. Med. Hyg. (1994) 88:344-345.
91. TORRES JR, ISTURIZ R, MURILLO J, GUZMAN M, CONTRERAS R: Efficacy of ivermectin in the treatment of strongyloidiasis complicating AIDS. Clin. Infect. Dis. (1993) 17:900-902.
92. MILNER PF, IRVINE RA, BARTON CJ, BRAS G, RICHARDS R: Intestinal malabsorption in Strongyloides stercoralis infestation. Gut (1965) 6:574-581.
93. KOBAYASHI J, SATO Y, TOMA H, TASAKI T, TAKARA M, SHIROMA Y: Sex-related different efficacy of chemotherapy on human strongyloidiasis in Okinawa, Japan. Jpn. J. Parasitol. (1996) 45:350-350.
94. KOBAYASHI J, SATO Y, TOMA H, TAKARA M, SHIROMA Y: Application of enzyme immunoassay for postchemotherapy evaluation of human strongyloidiasis. Diag. Microbiol. Infect. Dis. (1994) 18 19-23.
95. RAMACHANDRAN S, THOMPSON RW, GAM AA, NEVA FA: Recombinant cDNA clones for immunodiagnosis of strongyloidiasis. J. Infect. Dis. (1998) 177:196-203.
96. WALZER P, MILDER JE, BANWELL JG, KILGORE G, KLEIN M, PARKER R: Epidemiological features of Strongyloides stercoralis infection in an endemic area of the United States. Am. J. Trop. Med. Hyg. (1982) 31:313-319.
97. SATOH M, TOMA H, KIYUNA S, SHIROMA Y, KOKAZE A, SATO Y: Association of a sex-related difference of Strongyloides stercoralis-specific IgG4 antibody titre with the efficacy of treatment of strongyloidiasis. Am. J. Trop. Med. Hyg. (2004) 71:107-111.